HeimARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
17,32 $
Eftir lokun(0,00%)0,00
17,32 $
Lokað: 12. sep., 16:03:25 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
18,04 $
Dagbil
16,54 $ - 17,83 $
Árabil
8,04 $ - 25,88 $
Markaðsvirði
470,32 m. USD
Meðalmagn
643,00 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 28,30 m. | -43,24% |
Rekstrarkostnaður | 36,59 m. | -45,07% |
Nettótekjur | -9,18 m. | 46,68% |
Hagnaðarhlutfall | -32,44 | 6,05% |
Hagnaður á hvern hlut | -0,34 | 46,88% |
EBITDA | -10,84 m. | 46,40% |
Virkt skatthlutfall | -0,04% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 196,47 m. | -24,53% |
Heildareignir | 309,27 m. | -20,42% |
Heildarskuldir | 78,22 m. | -39,84% |
Eigið fé alls | 231,05 m. | — |
Útistandandi hlutabréf | 27,15 m. | — |
Eiginfjárgengi | 2,12 | — |
Arðsemi eigna | -9,06% | — |
Ávöxtun eigin fjár | -10,87% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -9,18 m. | 46,68% |
Handbært fé frá rekstri | -5,76 m. | 80,91% |
Reiðufé frá fjárfestingum | 0,00 | 100,00% |
Reiðufé frá fjármögnun | -14,73 m. | -712,82% |
Breyting á handbæru fé | -20,48 m. | 27,03% |
Frjálst peningaflæði | -19,72 m. | 23,68% |
Um
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Framkvæmdastjóri
Stofnsett
2013
Vefsvæði
Starfsfólk
175
